Precision medicine innovator Closed Loop Medicine (CLM) appoints Kate Woolland as its new Chief Executive Officer, marking a significant leadership transition as the company enters a commercialization-focused phase.
Lord David Prior (left) joins Shift Bioscience as Chair of the Board, alongside Sir Tony Kouzarides (right), appointed as Scientific Advisor, as the company accelerates its mission to combat aging through AI-driven therapeutics.
Lord David Prior brings a wealth of experience from his extensive career in healthcare and public service. His previous roles include Chairman of NHS England, the Care Quality Commission, and Parliamentary Under-Secretary of State for both the Department of Health and Social Care and the Department for Business, Energy and Industrial Strategy. In his new position at Shift Bioscience, Lord Prior will focus on advancing the company's long-term strategy to reverse aging and will leverage his industry knowledge to explore investment opportunities and accelerate the development of Shift's therapeutic pipeline through partnerships with pharmaceutical companies.
Sir Tony Kouzarides is a distinguished academic and entrepreneur with significant contributions to the life sciences sector. He is a Professor of Cancer Biology at the University of Cambridge, a senior group leader at the Gurdon Institute, and co-founder of the Milner Therapeutics Institute and Abcam. As Scientific Advisor, Sir Tony will guide Shift Bioscience's scientific strategy, identify research and industry opportunities, and enhance awareness of the company's unique approach to cell rejuvenation therapeutics.
Dr. Daniel Ives, CEO of Shift Bioscience, expressed enthusiasm about the new appointments: "I'm extremely pleased to welcome Lord David Prior and Sir Tony Kouzarides to Shift Bioscience. Both are hugely renowned leaders in healthcare and life sciences respectively, and their careers and achievements speak for themselves. We're incredibly thankful for their support of our mission to reverse aging and combat the debilitating diseases that come with it, and I look forward to harnessing their experience to help propel the company forwards in pursuit of this goal."
Shift Bioscience
Shift Bioscience employs advanced machine learning techniques to measure epigenetic changes, enabling the identification of genes that can reverse or slow down the aging process. The company's innovative approach holds promise for transitioning from a reactive "sick-care" system to a proactive, preventative healthcare model.
